Previous 10 | Next 10 |
2023-10-27 02:23:19 ET ETFs: ( EWA ), ( FXA ), ( FLAU ). Currency: ( USD:AUD ) More on Australia economy: Australia's services sector rises to 51.8; composite PMI 4-month high in September RBA keeps interest rate on hold at 4.10% in ...
2023-10-27 02:02:10 ET Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber - President and Chief Executive Officer Andy Pl...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK) is expected to report for Q2 2024
2023-10-26 02:26:28 ET More on Takeda Pharmaceutical Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade) Takeda fails in second Phase 3 trial for CPF therapy Alofisel Taked...
Revenue Growth of +6.4% at Actual Exchange Rate (AER); +1.4% Growth at Constant Exchange Rate (CER), Driven by Growth & Launch Products (+13% at CER) Core Operating Profit Year-on-Year Change of -9.5% at CER Reflecting Generic Impact, Lower Demand for Coronavirus Vaccines and Incr...
2023-10-24 14:43:31 ET Summary High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to meet key endpoints, thus impacting the company's FY23 outlook. When the company reports Q2 earn...
2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...
2023-10-19 18:23:58 ET Summary Hutchmed's 2023 interim financial report shows progress towards profitability, with revenue from product sales and R&D services increasing. The company has a strong balance sheet with $856 million in cash and a low level of bank borrowings. T...
Approval Based on Updated Positive Overall Survival Results from the Phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma First Significant Improvement in Overall Survival in Two Decades in Stage III & IV Hodgkin Lymphoma Approval Expands on Six Current Indi...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Pharmaceutical Company Limited American Depositary Shares Website:
2024-07-04 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...
LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase 1 CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Secondary Infections and Serious Consequences, Including Loss of Trans...